Paroxetine for hot flashes
Paroxetine at 7.5 mg (Brisdelle) is the only non-hormonal, non-antidepressant medication FDA-approved specifically for menopausal hot flashes.
How it works
Brisdelle uses a lower dose than typical antidepressant paroxetine and targets serotonin reuptake inhibition in the hypothalamus, where serotonin signaling plays a role in thermoregulatory stability after estrogen decline. The FDA approval was based on randomized controlled trials showing approximately 40–60% reduction in hot flash frequency versus placebo's 30% — a modest but statistically significant and clinically meaningful margin. Onset is typically within one to two weeks. Unlike standard-dose paroxetine, Brisdelle was specifically studied and labeled for vasomotor symptoms, giving physicians and patients a clearer evidence base than off-label SSRI use.
A clinically important interaction: paroxetine is a potent CYP2D6 inhibitor, which means it can significantly reduce the efficacy of tamoxifen. Women on tamoxifen for breast cancer should discuss this interaction explicitly with their oncologist before starting paroxetine. Other SSRIs with weaker CYP2D6 inhibition (such as escitalopram) are often preferred in that context. Side effects at the 7.5 mg dose are generally mild but can include nausea, dry mouth, and changes in libido.
How to track Paroxetine for hot flashes
- Hot flash frequency per day — the primary outcome measure in the Brisdelle approval trials, and the most direct signal of whether the drug is working.
- Hot flash severity — frequency alone doesn't capture how disruptive episodes are; a severity rating alongside count gives your physician a fuller picture.
- Onset timeline — tracking from day one shows whether benefit appears within the expected one-to-two-week window.
- Nausea and dry mouth — the most common side effects at the 7.5 mg dose; usually mild and often transient.
- Libido changes — SSRIs at any dose can affect sexual function; worth logging separately from other mood or energy changes.
- Establish a hot flash baseline before starting — even five to seven days of pre-treatment logging gives you a comparison point to measure the 40–60% reduction the trials demonstrated.
- Log daily for the first four weeks; the first two weeks will show whether you're an early responder, and weeks three to four are when most trial response is measured.
- If you are also on tamoxifen, log that you disclosed this to your oncologist and the date of that discussion — the CYP2D6 interaction is clinically significant and should be documented.
- Rate nausea and dry mouth separately from hot flash severity in the first two weeks; they often resolve as your body adjusts.
- Note libido and sexual function changes as a separate log item — these are meaningful for quality of life and are easy to overlook when focused on hot flash tracking.
Questions to ask your physician
- My pre-treatment baseline was [X] hot flashes per day. At [N] weeks on Brisdelle, my daily average is [Y]. Is that response within the expected range from the approval trials?
- I've been tracking nausea at [frequency/severity] — is that typical for the 7.5 mg dose, and is it expected to resolve?
- My severity log shows [pattern] — frequency has changed but severity has [improved/not changed]. Does that distinction matter for dose decisions?
- I have been logging libido changes since starting — here is the pattern. Is that a known effect at this dose, and does it warrant a medication change?